1ST-102

N/A

Report date: 2025/01/26 15:18:11
NME

Base Information

Drug Name1ST-102
Drug Alias Namec-Abl kinase inhibitor (1ST Biotherapeutics/Neuraly)cellular Abelson tyrosine kinase inhibitor (1ST Biotherapeutics/Neuraly)1ST-102
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitors
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsNerve DegenerationAlzheimer DiseaseParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSouth Korea
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator Companies1st Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active Companies1st Biotherapeutics IncNeuraly Inc
Inactive CompaniesN/A
Active IndicationsNerve DegenerationAlzheimer DiseaseParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A